Retatrutide — the strongest weight-loss data ever published. Still unproven.

The 24% number gets quoted everywhere the molecule is sold. What gets left out, almost every time: it came from a phase 2 trial of 338 people, over 48 weeks, for a drug no regulator has approved. Both halves of that sentence are true. Here is the whole picture.

The number that sells vials

Spend ten minutes where research peptides are discussed and you will meet the 24% figure. It appears in vendor product descriptions, group-buy threads, and social clips with the confidence of settled science — usually next to language that quietly positions retatrutide as the successor to tirzepatide, one tier up in some finished hierarchy. What almost never travels with the number: the phase, the sample size, the duration, or the fact that no regulator on earth has reviewed this molecule for approval.

That omission is not an accident. A phase 2 result stripped of its context is a better sales asset than a phase 2 result with its context attached. Our job here is the opposite of a sales asset, so we will give you both — the data, which is genuinely remarkable, and the boundaries of the data, which the market has strong incentives to blur.

What a triple agonist is

Semaglutide — sold as Ozempic, Wegovy, and Rybelsus — activates one receptor: GLP-1. Tirzepatide — Mounjaro and Zepbound — activates two: GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and the glucagon receptor. That third target is the new mechanism, and it changes the character of the drug.

GLP-1 and GIP agonism work mainly on the intake side — appetite suppression, slower gastric emptying, improved glycemic signaling. Glucagon-receptor agonism is thought to add an expenditure effect: increased energy use, with hepatic effects that showed up in the trial data as well. In plain terms, the first two mechanisms help you eat less, and the third may help you burn more. Whether that combination is a breakthrough or a trade-off with costs that only appear at scale is exactly the kind of question phase 2 trials are too small to answer.

What the phase 2 trial showed

The trial to know is Jastreboff and colleagues, published in the New England Journal of Medicine in 2023. Roughly 338 adults with obesity, randomized across placebo and several retatrutide doses, followed for 48 weeks. On the highest dose — 12 mg weekly — mean weight reduction was approximately 24%. Two details matter as much as the headline figure.

First, the dose-response was clean: more drug, more loss, in an orderly pattern across arms. Second, and more striking, the weight-loss curves had not plateaued at 48 weeks. Participants on the higher doses were still losing when the trial ended. For comparison, semaglutide's and tirzepatide's pivotal trials ran 68 and 72 weeks and captured something closer to a full arc. Retatrutide's 24% is, in a sense, an unfinished number — which cuts both ways. The final figure could be higher. It could also come with problems a 48-week window never had time to reveal.

The three trials, side by side — with a warning label

Here is the comparison everyone makes, in table form. Read the warning under it before you repeat it.

The warning label: these are three different trials with different durations, different populations, different eras of obesity-trial design, and different phases of evidence. Lining their numbers up in one table — as we just did, as everyone does — is indicative, not head-to-head. No published trial has put retatrutide in the same room as tirzepatide or semaglutide. The honest reading is that retatrutide's mid-stage data points toward something larger than the approved drugs achieved in late-stage trials. The dishonest reading, which you will encounter daily, is that a ranking has been established. It has not.

The side-effect profile, without the airbrush

The tolerability story in the phase 2 trial was the familiar incretin story, scaled to a stronger drug. Adverse events were dominated by gastrointestinal effects — nausea, vomiting, diarrhea, constipation — and they were dose-dependent and concentrated during dose escalation, the same pattern semaglutide and tirzepatide established before it. The trial used gradual dose escalation specifically to manage this, and slower escalation appeared to help.

Two things follow from that. First, retatrutide is not a free lunch; the strongest efficacy data ever published came with a real GI burden, experienced at pharmaceutical-grade purity under medical supervision. Second, the glucagon-receptor mechanism adds physiology the older drugs do not touch — heart-rate observations in the trial drew attention, and effects involving new mechanisms are precisely what small trials are underpowered to characterize. That is not a reason for alarm. It is the reason phase 3 exists. For a grounded look at what incretin-class side effects look like in practice, our side-effects fundamentals page covers the class.

What phase 3 still has to prove

Lilly's phase 3 program is called TRIUMPH, and it is running now, registered on clinicaltrials.gov. Until it reads out and regulators rule, three questions stay open — and they are not small ones.

Durability. The phase 2 curves were still falling at 48 weeks. Where do they land at 68 or 80 weeks, and what does maintenance look like? Every drug in this class shows regain after discontinuation; how retatrutide behaves over a full arc is simply unknown.

Safety at scale. A 338-person trial can find common side effects. It cannot find the one-in-two-thousand harm. Phase 3 programs enroll thousands of participants across many sites because that is the only way rare events surface. Tirzepatide and semaglutide have cleared this bar and accumulated years of post-approval exposure. Retatrutide has not started it in earnest.

Cardiovascular outcomes. The approved incretins built their standing partly on cardiovascular-outcome data. Retatrutide's glucagon component makes this question sharper, not softer — a mechanism that raises energy expenditure needs its cardiovascular story told in a large trial, not inferred from a mid-stage one.

The gray market is not waiting

Here is the collision at the center of this article. The evidence base says: promising, mid-stage, unproven. The market says: in stock. Retatrutide is one of the most widely sold molecules in the research-compound economy right now — vialed, labeled, and shipped by vendors who range from genuinely rigorous to functionally anonymous. None of it is pharmaceutical product. All of it exists outside the approval framework, which means no regulator has verified what is in any given vial.

The quality spread in that market is the real story, and we have covered it at length. Purity, identity, fill accuracy, and endotoxin load vary lot to lot and vendor to vendor, and the paperwork that is supposed to document them is frequently missing, recycled, or decorative. If you are evaluating that market at all, two of our reports are the necessary background: how to read a certificate of analysis — the five measures that matter and how to catch a fake — and where peptide powder actually comes from, which traces the supply chain those certificates are supposed to describe. The regulatory pressure building around that supply chain is its own story, covered in our 2026 policy report.

What you will not find here is a dosing protocol. This is an evidence piece, and the evidence for this molecule comes from a trial whose escalation schedule was designed for a drug of known purity under medical supervision — conditions the gray market does not reproduce. General principles of how research dosing is discussed live in our dosing fundamentals, and our compound index holds the profile pages.

How to hold both facts at once

The strongest weight-loss data ever published. Still unproven. The market treats these as contradictory, and picks whichever half sells. They are not contradictory — they are the normal state of a drug between phase 2 and phase 3, and most drugs that look this good mid-stage do go on to approval, sometimes with surprises attached. The 24% number deserves the attention it gets. The 338-person, 48-week, unapproved context deserves to travel with it, every time. When you see the number without the context, you have learned something about the source.

FAQ

References & further reading

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity [SURMOUNT-1]. N Engl J Med. 2022;387:205-216.
3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity [STEP 1]. N Engl J Med. 2021;384:989-1002.
4. Lilly's TRIUMPH phase 3 program for retatrutide — trial registrations at clinicaltrials.gov
5. Inside Your Peptides, How to Read a COA — the five measures that matter
6. Inside Your Peptides, Where Peptide Powder Comes From — the supply-chain report

disclosure: inside your peptides may earn referral fees from vendor links elsewhere on this site — this article carries none. grades and rankings follow the published criteria in our editorial policy — never referral terms. research + education only · not medical advice.